SIPI 7623
Alternative Names: SIPI-7623Latest Information Update: 07 Oct 2021
At a glance
- Originator Jiangsu Carephar Pharmaceutical
- Class Acetamides; Antihyperlipidaemics; Phenyl ethers; Small molecules
- Mechanism of Action Farnesoid X activated receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypercholesterolaemia
Most Recent Events
- 01 Oct 2021 Chemical structure information added
- 28 Sep 2021 Phase-I clinical trials in Hypercholesterolaemia in China (unspecified route) before September 2021 (Jiangsu Carephar Pharmaceutical pipeline, September 2021)